 JERSEY CITY, N.J., July 02, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to four new employees to purchase an aggregate of 18,100 shares of SCYNEXIS common stock at a per share exercise price of 7.36, the closing trading price on June 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS offers of employment. 